相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Influence of CYP3A5 and SLCO1B1 polymorphisms on atazanavir/r concentrations in Thai HIV-infected patients
Noppaket Singkham et al.
PHARMACOGENOMICS (2019)
Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs
Andrea Calcagno et al.
CLINICAL PHARMACOKINETICS (2017)
Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients
Baralee Punyawudho et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Role and modulation of drug transporters in HIV-1 therapy
Camille Alam et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients
Jose Molto et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)
Jose R. Castillo-Mancilla et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial
Torsak Bunupuradah et al.
LANCET HIV (2016)
Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature
Stefan Wolking et al.
CLINICAL PHARMACOKINETICS (2015)
Pharmacogenetic Testing Can Identify Patients Taking Atazanavir at Risk for Hyperbilirubinemia
Anchalee Avihingsanon et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2015)
Pharmacokinetic Enhancers in HIV Therapeutics
Kajal B. Larson et al.
CLINICAL PHARMACOKINETICS (2014)
Evaluation of Boosted and Unboosted Atazanavir Plasma Concentration in HIV Infected Patients
Silvia Amadasi et al.
CURRENT HIV RESEARCH (2014)
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms
Antonio D'Avolio et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202
Charles S. Venuto et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Pharmacokinetic-Pharmacodynamic Modeling of Unboosted Atazanavir in a Cohort of Stable HIV-Infected Patients
Sylvain Goutelle et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin
Chao Zhang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies
Alessandro Schipani et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose
R. J. Keizer et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
Genetic contribution to variable human CYP3A-mediated metabolism
Jatinder K. Lamba et al.
ADVANCED DRUG DELIVERY REVIEWS (2012)
A Population Pharmacokinetic-Pharmacogenetic Analysis of Atazanavir
Deidre A. Kile et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2012)
Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment-Naive HIV-Infected Patients
R. M. Savic et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
PharmGKB summary: very important pharmacogene information for CYP3A5
Jatinder Lamba et al.
PHARMACOGENETICS AND GENOMICS (2012)
Nuclear receptor PXR, transcriptional circuits and metabolic relevance
Chibueze A. Ihunnah et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2011)
Influence of Drug Transport Proteins on the Pharmacokinetics and Drug Interactions of HIV Protease Inhibitors
Latoya Griffin et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
CYP3A5, ABCB1, and SLCO1B1 Polymorphisms and Pharmacokinetics and Virologic Outcome of Lopinavir/Ritonavir in HIV-Infected Children
Natella Y. Rakhmanina et al.
THERAPEUTIC DRUG MONITORING (2011)
The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: A Global Proficiency Testing Program
David Burger et al.
THERAPEUTIC DRUG MONITORING (2011)
Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance
Alessandro Schipani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Factors influencing lopinavir and atazanavir plasma concentration
Wolfgang Stoehr et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
A Low Dose of Ritonavir-Boosted Atazanavir Provides Adequate Pharmacokinetic Parameters in HIV-1-Infected Thai Adults
A. Avihingsanon et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Atazanavir A Review of its Use in the Management of HIV-1 Infection
Katherine F. Croom et al.
DRUGS (2009)
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers
Laura Dickinson et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors
Peter L. Anderson et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C→T) with reduced concentrations of unboosted atazanavir
Marco Siccardi et al.
CLINICAL INFECTIOUS DISEASES (2008)
Population Pharmacokinetics of Atazanavir in Human Immunodeficiency Virus-Infected Patients
Caroline Solas et al.
THERAPEUTIC DRUG MONITORING (2008)
Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients
Caroline Solas et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Antiretroviral pharmacokinetic profile: A review of sex differences
Ighovwerha Ofotokun et al.
GENDER MEDICINE (2007)
Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia
Sonia Rodriguez-Novoa et al.
AIDS (2007)
Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection
Sara Colombo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients
Eric Dailly et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy
A Winston et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir
C Le Tiec et al.
CLINICAL PHARMACOKINETICS (2005)
A new equivalence based metric for predictive check to qualify mixed-effects models
PR Jadhav et al.
AAPS JOURNAL (2005)
Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients
AM Taburet et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Model appropriateness and population pharmacokinetic modeling
EL Ette et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
分享论文
